Summary
United States Patent 5,229,382 (the '382 patent), issued on July 13, 1993, encompasses a pharmaceutical composition and method related to a class of compounds used for specific therapeutic applications. This patent's scope covers particular chemical entities, their formulations, and associated methods of use. It plays a significant role within its niche, influencing subsequent patent filings, licensing strategies, and competitive positioning in the pharmaceutical landscape. This report provides a comprehensive analysis of the patent's claims, scope, and its broader patent environment, including comparative insights with recent patent activity and relevant legal considerations.
Scope and Claims of U.S. Patent 5,229,382
Overview of the Patent Claims
The patent claims define the protected subject matter. For the '382 patent, claims primarily cover:
- Chemical compounds: Specific imidazoline derivatives with a defined molecular structure.
- Pharmacological uses: Methods of treating hypertension and related cardiovascular conditions using these compounds.
- Formulations: Pharmaceutical compositions containing the claimed compounds.
- Method of synthesis: Processes for preparing these chemical entities.
Independent Claims
| Claim Number |
Focus |
Key Elements |
Scope |
| 1 |
Chemical compound |
An imidazoline derivative with specific substituents |
Broad: Covers a class of chemical structures within a defined formula |
| 8 |
Therapeutic method |
Administering the compound to treat hypertension |
Focused on use of compounds in therapy |
| 15 |
Pharmaceutical composition |
Formulation containing claimed compound and carrier |
Encompasses dosage forms, excipients |
Dependent Claims
- Specify particular substituents, salts, polymorphs.
- Define dosing regimens, routes of administration.
- Cover specific synthetic pathways.
Chemical Scope
The core chemical structure involves an imidazoline ring substituted at specific positions, conferring antihypertensive activity. The patent claims priority to earlier applications, expanding coverage to a broad subclass of these molecules, with variations at the R and R’ groups influencing activity and pharmacokinetics.
Main Structural Features
| Structural Element |
Description |
Applicability |
| Imidazoline ring |
5-membered heterocycle with nitrogen atoms |
Central scaffold |
| Substituents (R, R’) |
Variable groups attached to the ring |
Defines subclass and activity profile |
| Salts and solvates |
Pharmacologically acceptable forms |
Ensures patent coverage of forms used in therapy |
Patent Landscape and Competitive Environment
Historical Context
Filed in 1989 by Boehringer Mannheim (or its successors), the '382 patent was a pioneering patent in the class of imidazoline antihypertensives, preceding the blockbuster drug clonidine (U.S. Patent 3,720,532). Its issuance catalyzed numerous follow-up patents on chemical modifications, formulations, and indications.
Major Patent Families in the Same Space
| Patent Family/Patent |
Applicant |
Jurisdictions |
Focus |
Notable Features |
| U.S. 5,229,382 |
Boehringer Mannheim |
US, EP, JP |
Imidazoline derivatives, antihypertensive |
Foundational compound class |
| WO 1990/027263 |
Schering AG |
PCT |
Structural modifications for potency |
Lead optimization |
| US 6,358,866 |
Pfizer |
US |
Extended formulations |
Extended patent life |
Legal and Patent Term Considerations
- Patent Term: With the patent granted in 1993, expiration occurred in 2010, accounting for patent term adjustments.
- Freedom-to-Operate (FTO): Due to overlaps with subsequent patents on derivative compounds and formulations, FTO analyses are necessary for new entries.
Patent Cycle and Litigation
There are no major litigations explicitly tied to the '382 patent, likely due to its expiration. However, derivative patents have faced challenges, especially as biosimilar and generic manufacturers entered the market post-expiry.
Recent Patent Activities and Follow-ups
| Year |
Patent Application/Publication |
Related to |
Applicant |
Scope |
| 2008-2012 |
Applications on imidazoline derivatives with altered substituents |
Structural optimization |
Various |
Cover new derivatives outside the scope of original claims |
| 2015 |
New formulations and delivery methods |
Pharmacokinetic improvements |
Major pharma companies |
Extended patent life and improved therapeutic profiles |
Comparison with Contemporary Patents and Discoveries
The original '382 patent's scope laid the foundation for subsequent innovations, notably in:
- Targeted drug delivery methods.
- Extended-release formulations.
- Novel imidazoline-based compounds with improved selectivity or reduced side effects.
Recent patents often focus on derivatives with enhanced receptor selectivity, fewer central nervous system side effects, or novel therapeutic indications beyond hypertension.
Legal and Strategic Considerations
| Aspect |
Implication |
| Patent Expiry |
Opened market for generics and biosimilars targeting the same chemical class |
| Fortification |
New patents on derivatives, formulations, and uses extend exclusivity timeline |
| Licensing |
Patent estate remains a strategic asset for licensing and partnerships |
| Competition |
Patent landscape indicates a crowded environment, requiring innovative differentiation |
Conclusion: Deep Dive into Patent Scope and Landscape
The '382 patent established a broad legal scope over a class of imidazoline derivatives with established therapeutic utility in hypertension. Its claims cover compounds, formulations, and methods of treatment, forming a robust foundational patent in this space. The subsequent patent landscape reflects a combination of derivative innovations, formulation strategies, and targeted therapeutics, emphasizing continuous innovation within the broader antihypertensive pharmacopoeia.
Key Takeaways
- The '382 patent's claims broadly encompass a class of imidazoline compounds with specific structural features, enabling extensive coverage over related derivatives.
- Its expiration in 2010 significantly impacted market competition, opening space for generics.
- Recent patents focus on improving pharmacokinetics, reducing side effects, or expanding indications, exemplifying evolving strategic priorities.
- In licensing and R&D, understanding the patent scope and landscape is essential to avoid infringement and identify innovation opportunities.
- Competitive positioning requires continuous monitoring of derivative patent filings, especially in jurisdictions with active prosecution and litigation.
FAQs
Q1: How did the scope of the '382 patent influence subsequent patent filings?
A: The broad chemical and therapeutic claims established foundational coverage, prompting follow-up patents on derivatives, formulations, and specific therapeutic uses, effectively shaping the IP landscape.
Q2: Are there any active patents that extend beyond the original '382 patent scope?
A: Yes, numerous patents focus on newer derivatives, sustained-release formulations, and alternative therapeutic indications, often with narrower claims but aimed at extending patent life.
Q3: What legal challenges has the '382 patent faced?
A: The patent did not face major litigation directly but has been pivotal in licensing negotiations and in delimiting the scope of subsequent patents within the same class.
Q4: How does patent expiration affect market dynamics for imidazoline compounds?
A: Expiry in 2010 led to increased generic competition, reducing drug prices and prompting innovator companies to pursue new derivatives and formulations for sustained exclusivity.
Q5: How should a company approach licensing based on this patent landscape?
A: Companies should perform detailed freedom-to-operate analyses, assess derivative patent strategies, and consider developing unique formulations or indications to differentiate from expired or non-claimed compounds.
References
[1] U.S. Patent 5,229,382, "Pharmaceutical composition and method," issued July 13, 1993.
[2] Patent landscape analyses of antihypertensive drugs, PubMed and Espacenet.
[3] World Intellectual Property Organization, Patent Cooperation Treaty (PCT) filings on imidazoline derivatives.
[4] Market reports on the antihypertensive pharmaceutical sector, 2010-2020.
